Literature DB >> 11939266

Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia.

Masahiro Masuya1, Naoyuki Katayama, Koichi Inagaki, Hiroshi Miwa, Natsuki Hoshino, Hiroyuki Miyashita, Hirohito Suzuki, Hiroto Araki, Hidetsugu Mitani, Kazuhiro Nishii, Shin-ichi Kageyama, Nobuyuki Minami, Hiroshi Shiku.   

Abstract

We describe a 55-year-old Japanese woman with therapy-related myelodysplastic syndrome (t-MDS) with 2 independent clones, t(1;2)(p36;p21) and t(11;12)(pl5;ql3). She was diagnosed with acute myeloid leukemia (AML) with cytological features of the bone marrow and peripheral blood. Cytogenetic evaluation revealed a 46,XX karyotype. She received chemotherapy and achieved complete remission (CR). Despite maintenance chemotherapy, she suffered a relapse. Chromosomal analysis showed t(1;2)(p36;p21) in 2 of 20 metaphases. At second CR, this clone transiently disappeared. Nine months later, t(1;2) (p36;p21) was detected again in 3 of 20 metaphases while the patient remained in CR. Six months later, bone marrow examination disclosed trilineage dysplasia without an excess of blasts, suggesting MDS. t(1;2)(p36;p21) was observed in 16 of 20 metaphases. The clinical course and serial cytogenetic findings were diagnostic of t-MDS. The duration of t-MDS was 6 years. During this period, persistent t(1;2)(p36;p21) and transient t(11;12)(p15;q13) were found. When t-MDS evolved toAML, cytogenetic evaluation revealed 46,XX,t(1;2)(p36;p21),del(7)(q22),add(19)(p13).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939266     DOI: 10.1007/BF02982025

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

Review 1.  Therapy-related myelodysplastic syndromes.

Authors:  D J Park; H P Koeffler
Journal:  Semin Hematol       Date:  1996-07       Impact factor: 3.851

2.  Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia.

Authors:  F Mitelman; L Brandt; P G Nilsson
Journal:  Blood       Date:  1978-12       Impact factor: 22.113

3.  A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.

Authors:  N Mochizuki; S Shimizu; T Nagasawa; H Tanaka; M Taniwaki; J Yokota; K Morishita
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

4.  De novo AML with trilineage myelodysplasia and a novel t(11;12)(p15;q13).

Authors:  K F Wong; Y L Kwong; C C So
Journal:  Cancer Genet Cytogenet       Date:  1998-01-01

5.  Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases.

Authors:  J Pedersen-Bjergaard; S Timshel; M K Andersen; A S Andersen; P Philip
Journal:  Genes Chromosomes Cancer       Date:  1998-12       Impact factor: 5.006

6.  Cytogenetic biclonality in malignant hematologic disorders.

Authors:  T Furuya; R Morgan; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1992-08

7.  Mapping of the gene for interferon-inducible dsRNA-dependent protein kinase to chromosome region 2p21-22: a site of rearrangements in myeloproliferative disorders.

Authors:  S M Hanash; L Beretta; C L Barcroft; S Sheldon; T W Glover; D Ungar; N Sonenberg
Journal:  Genes Chromosomes Cancer       Date:  1993-09       Impact factor: 5.006

8.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1991-07       Impact factor: 6.998

9.  The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations.

Authors:  G Tricot; M A Boogaerts; C De Wolf-Peeters; H Van den Berghe; R L Verwilghen
Journal:  Br J Haematol       Date:  1985-04       Impact factor: 6.998

10.  Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings.

Authors:  A Cuneo; A Ferrant; J L Michaux; M Boogaerts; H Demuynck; A Van Orshoven; A Criel; M Stul; P Dal Cin; J Hernandez
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

View more
  3 in total

1.  Karyotypically independent clones with del(11q) and trisomy 10 in acute myeloid leukemia: trisomy 10 may appear as an additional change.

Authors:  Moritaka Gotoh; Yuko Sasaki; Tomotaka Iguchi; Hiroaki Fujimoto; Atsushi Kodama; Hitoshi Kiyoi; Tomoki Naoe; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2008-06-20       Impact factor: 2.490

2.  Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.

Authors:  S Herold; K Sockel; C Sayehli; R Herbst; U Dührsen; U Oelschlägel; A Böttner; H Hindahl; J Kullmer; S Helas; M Sauer; B Mohr; A Mies; M Bornhäuser; G Ehninger; C Röllig; C Thiede; U Platzbecker
Journal:  Leukemia       Date:  2017-07-10       Impact factor: 11.528

3.  Acute monocytic leukaemia with t(11; 12) (p15; q13) chromosomal changes: A case report and literature review.

Authors:  Jiasheng Hu; Xiuli Hong; Zhe Li; Quanyi Lu
Journal:  Oncol Lett       Date:  2015-07-20       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.